No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
KRON240719C7500
- 0.05
- 0.000.00%
15min DelayTrading Jun 11 10:13 ET
0.00High0.00Low
0.00Open0.05Pre Close0 Volume29 Open Interest7.50Strike Price0.00Turnover2414.87%IV467.24%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier0DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1112Delta0.1418Gamma26.63Leverage Ratio-0.1916Theta0.0000Rho2.96Eff Leverage0.0001Vega
Intraday
- 5D
- Daily
News
Kronos Bio(KRON.US) Officer Buys US$733.8K in Common Stock
$Kronos Bio(KRON.US)$ Officer BISCHOFBERGER NORBERT W purchased 615.52K shares of common stock on Jun 27, 28, 2024 at an average price of $1.1922 for a total value of $733.8K.Source: Announcement What
Shareholders May Be More Conservative With Kronos Bio, Inc.'s (NASDAQ:KRON) CEO Compensation For Now
Increases to Kronos Bio, Inc.'s (NASDAQ:KRON) CEO Compensation Might Cool off for Now
Key Insights Kronos Bio to hold its Annual General Meeting on 25th of June Total pay for CEO Norbert Bischofberger includes US$580.0k salary The total compensation is 55% higher than the average f
President of Kronos Bio Picks Up 36% More Stock
Kronos Bio, Inc. (NASDAQ:KRON) shareholders (or potential shareholders) will be happy to see that the President, Norbert Bischofberger, recently bought a whopping US$3.1m worth of stock, at a price of
Insider Spends US$3.1m Buying More Shares In Kronos Bio
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersLongeveron (NASDAQ:LGVN) stock increased by 74.6% to $3.16 during Thursday's regular session. The company's market cap stands at $20.0 million. BioRestorative Therapies (NASDAQ:BRTX) stock rose
Comments
$Kronos Bio(KRON.US$
NEWS
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Kronos Bio announced new data from its Phase 1/2 trial of KB-0742, presented at the 2024 ASCO Annual Meeting. KB-0742 showed a manageable safety profile with no grade 3/4 neutropenia observed. Dose linear pharmacokinetics were consistent up to 80mg, and increased target engagement was noted at higher doses. The 80mg four-days-on, t...
NEWS
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Kronos Bio announced new data from its Phase 1/2 trial of KB-0742, presented at the 2024 ASCO Annual Meeting. KB-0742 showed a manageable safety profile with no grade 3/4 neutropenia observed. Dose linear pharmacokinetics were consistent up to 80mg, and increased target engagement was noted at higher doses. The 80mg four-days-on, t...
2
$Kronos Bio(KRON.US$ Kronos Bio Says Phase 1b Portion Of Phase 1b/2 Lanraplenib Study Does Not Support Continuing To Phase 2![]()
3
Gainers:
• $Cogent Biosciences(COGT.US$ +7.9% (announces positive initial clinical data from ongoing phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis)
• $Univar Solutions(UNVR.US$ +7.2% (expands distribution partnership with BASF)
• $Vail Resorts(MTN.US$ +6% (In reaction to earnings/guidance)
• $BeiGene(BGNE.US$ +5.4% (highlights growing portfolio and pipeline targeting hematologic mali...
• $Cogent Biosciences(COGT.US$ +7.9% (announces positive initial clinical data from ongoing phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis)
• $Univar Solutions(UNVR.US$ +7.2% (expands distribution partnership with BASF)
• $Vail Resorts(MTN.US$ +6% (In reaction to earnings/guidance)
• $BeiGene(BGNE.US$ +5.4% (highlights growing portfolio and pipeline targeting hematologic mali...
18
7
$Westwater Resources(WWR.US$ go buy these IPO I mentioned few days ago $Kronos Bio(KRON.US$ and $iHuman(IH.US$
5
1
Read more